(Q45007190)

English

Self-inactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Self-inactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

author name string

Azim Mohamedali

1

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Francois Moreau-Gaudry

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Emmanuel Richard

3

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Ping Xia

4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Punam Malik

6

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

publication date

1 August 2004

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Molecular Therapy

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

249-259

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Trends in leukemia incidence and survival in the United States (1973–1998)

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Specific targeted therapy of chronic myelogenous leukemia with imatinib

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Cytogenetic and molecular mechanisms of resistance to imatinib

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Imatinib alone and in combination for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

STI571 as a targeted therapy for CML.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Comparison of two PCR-based methods and automated DNA sequencing for prop-1 genotyping in Ames dwarf mice.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Advances in targeted therapy for chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: A targeted approach to enhance apoptosis

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

https://api.crossref.org/works/10.2217%2F14750708.1.2.249

21 January 2018

Identifiers

10.2217/14750708.1.2.249

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45007190&oldid=2062267577"